lung cancer

Oncology

ESMO26: Taiho Oncology on improving the lives of patients wi...

Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.

News

GSK showcases positive data with lung cancer drugs at WCLC

New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.

News

AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...

In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.

Oncology

EGFR-mutant lung cancer: Cracking the drug resistance code

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Patients

The hidden access gap in Europe’s lung cancer hospital data

New hospital-level analysis shows a provider landscape that is more concentrated, regionally uneven & strategically complex than commercially assumed.

ESMO26: Taiho Oncology on improving the lives of patients wi...

GSK showcases positive data with lung cancer drugs at WCLC

AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...

EGFR-mutant lung cancer: Cracking the drug resistance code

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

The hidden access gap in Europe’s lung cancer hospital data

Boehringer forges $7bn alliance with China's SBP Group

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks